Floatz logo

gi-6207

Prostate Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
59/ 100

Competitive context

427 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Degarelix
Bayer
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB
Flotufolastat F-18
Washington University School of Medicine
Phase 4BB
Estramustine
The University of Texas Health Science Center, Houston
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

gi-6207 is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
36 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →